Search
Adaptive Biotechnologies Corp
ADPTAdd to Watchlist
21.450USD
+0.050+0.23%
Close 06/30, 16:00（ET）Quotes delayed by 15 min
3.43BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+0.23%
5 Days
+24.49%
1 Month
+41.58%
6 Months
+32.08%
Year to Date
+32.08%
1 Year
+84.12%
Key Figures
21.350Open
21.546High
3.42MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.14%Turnover Ratio
21.400Prev. Close
20.705Low
59.94MTurnover
LossP/E Static
15.83P/B
0.00%Div Yield TTM
-9.76%ROA
20.76052wk High
0.79Volume Ratio
-159.49MNet Profit
159.70MShares
-0.3209EPS TTM
2.16Beta
-24.43%ROE
9.05052wk Low
3.93%Amplitude
73.01%Gross Margin
3.43BMarket Cap
10.54Reward/Risk
3.84%Risk Rate
TradingKey Stock Score of Adaptive Biotechnologies Corp
Currency: USD Updated: 2026-06-30Key Insights
Adaptive Biotechnologies Corp's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 11 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 20.50.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Adaptive Biotechnologies Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Adaptive Biotechnologies Corp Highlights
StrengthsRisks
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 62.66% year-on-year.
Undervalued
The company’s latest PE is -66.85, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 151.51M shares, decreasing 8.01% quarter-over-quarter.
Held by Andreas Halvorsen
Star Investor Andreas Halvorsen holds 30.08M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.99.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
20.500
Target Price
-4.21%
Upside Space
Adaptive Biotechnologies Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Adaptive Biotechnologies Corp Info
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
Ticker SymbolADPT
CompanyAdaptive Biotechnologies Corp
CEORobins (Chad M)
Websitehttps://www.adaptivebiotech.com
Related Instruments
-2.50%
-1.79%
-1.22%
-0.57%
-0.73%
-0.56%
+0.44%
-0.86%
+0.01%
-2.42%
-0.58%
-1.64%
-0.76%
-1.77%
+1.01%
0.00%
-1.31%
+1.68%
+0.56%
+0.28%Popular Instruments
52146.500
-49.800 (-0.10%)
30086.800
-137.800 (-0.46%)
7471.800
-10.600 (-0.14%)
15300.000
-295.000 (-1.89%)
70736.000
-120.000 (-0.17%)
6293.400
-33.600 (-0.53%)
69.028
-0.893 (-1.28%)
289.360
+7.620 (+2.70%)
200.090
+5.120 (+2.63%)
4030.360
+23.080 (+0.58%)
FAQs
What is the current price of Adaptive Biotechnologies Corp (ADPT)?
The current price of Adaptive Biotechnologies Corp (ADPT) is 21.45.
What is the symbol of Adaptive Biotechnologies Corp?
The ticker symbol of Adaptive Biotechnologies Corp is ADPT.
What is the 52-week high of Adaptive Biotechnologies Corp?
The 52-week high of Adaptive Biotechnologies Corp is 20.76.
What is the 52-week low of Adaptive Biotechnologies Corp?
The 52-week low of Adaptive Biotechnologies Corp is 9.05.
What is the market capitalization of Adaptive Biotechnologies Corp?
The market capitalization of Adaptive Biotechnologies Corp is 3.43B.
Is Adaptive Biotechnologies Corp (ADPT) currently rated as Buy, Hold, or Sell?
According to analysts, Adaptive Biotechnologies Corp (ADPT) has an overall rating of Buy, with a price target of 20.50.
What is the Earnings Per Share (EPS TTM) of Adaptive Biotechnologies Corp (ADPT)?
The Earnings Per Share (EPS TTM) of Adaptive Biotechnologies Corp (ADPT) is -0.39.